ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it …
especially with off-label usage and label expansion all very big parts of the ACAD stock story going forward. If Acadia struggles out the gate with Nuplazid, or encounters typical setbacks that one should expect from a first-time …
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) 2% HIGHER; In a 13G filing ...
The big question is whether big pharma values ACAD stock the same way that Acadia Pharmaceuticals management does. I think that’s the big disconnect right now. Acadia Pharmaceuticals has a market capitalization over $5 billion, …
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) traded down about 27% Monday to post a new 52-week low of $15.74 after closing Friday at $21.53. The stock’s 52-week high is $41.20. Volume was more 10 times the daily average of around 2 …
ACADIA Pharmaceuticals Inc. ACAD is scheduled to report second-quarter 2016 results on Aug 4 after the market closes. In the last reported quarter, ACADIA had posted a negative earnings surprise of -12.5%. Let’s see how things are …
The stock’s 52-week high is $48.62. Volume totaled around 15.2 million, about 20% above the daily average. The company had no specific news. Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) traded down about 20% Wednesday to post a …
ticker=ACAD Clovis Oncology, Inc. https://rdinvesting.com/news/?ticker=CLVS ACADIA Pharmaceuticals' stock moved 8.43% lower Wednesday, to close the day at $16.18. The stock recorded a trading volume of 5,283,123 shares, which …
Shares of major biotech companies stumbled Friday on concerns the sector may be overheated. The iShares NASDAQ …